ClinicalTrials.Veeva

Menu
A

Arkansas Children's | Arkansas Children's Hospital - Arkansas Children's Research Institute - Neurology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lasmiditan
LY573144
DEX
Dexmedetomidine
AOC 1044
Etrasimod
Pamrevlumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 9 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely ac...

Enrolling
Ulcerative Colitis
Drug: Etrasimod

AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multi...

Active, not recruiting
Exon 44
Duchenne Muscular Dystrophy
Drug: Placebo
Drug: AOC 1044

The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two...

Active, not recruiting
Duchenne Muscular Dystrophy
Other: Placebo
Genetic: PF-06939926

Trial sponsors

Pfizer logo
Lilly logo
Sarepta Therapeutics logo
A
FibroGen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems